Antacid therapy in idiopathic pulmonary fibrosis
Antacid therapy in idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of complex cause. Gastro-oesophageal reflux (GER) and microaspiration have been proposed as risk factors for the development and progression of IPF, but robust definitive data are few. A recent international guideline conditionally recommended the use of antacid therapy (proton pump inhibitors or histamine-2-receptor antagonists) for patients with IPF, in the absence of oesophageal reflux or symptoms. In this Position Paper, we summarise the literature addressing the association between GER and IPF, and also identify future research priorities that could clarify this issue. We shed light on the process through which the guideline recommendation was achieved and aim to contextualise the recommendation for providers caring for patients with IPF.
Antacids/therapeutic use, Disease Progression, Gastroesophageal Reflux/complications, Histamine H2 Antagonists/therapeutic use, Humans, Idiopathic Pulmonary Fibrosis/complications, Practice Guidelines as Topic, Proton Pump Inhibitors/therapeutic use, Risk Factors, Severity of Illness Index
591-598
Johannson, Kerri A.
f8af7188-2510-4c11-8a87-24b8d05c374c
Strâmbu, Irina
3dae037f-9dc6-4b35-9ef2-fb50ade0e6b6
Ravaglia, Claudia
785f7a4c-97f9-4912-a675-4be0992c220b
Grutters, Jan C.
684f7661-eab9-4d0f-97b6-45944fc899a0
Valenzuela, Claudia
80b6c1ba-7e18-4f0e-82a2-63c95da112e6
Mogulkoc, Nesrin
433ea942-9ac8-4c78-86a3-f1d003043852
Luppi, Fabrizio
7da8f1e6-4f08-4bcb-ae57-8bb3ce9032a5
Richeldi, Luca
47177d9c-731a-49a1-9cc6-4ac8f6bbbf26
Wells, Athol U.
47bba0f1-7cf9-4e3d-97b3-2be719a87357
Vancheri, Carlo
5f7ca838-5321-4639-ac93-0d924fd4bb73
Kreuter, Michael
f97455b8-d063-4e97-b0d2-c8bc715d04a2
Jones, Mark
a6fd492e-058e-4e84-a486-34c6035429c1
July 2017
Johannson, Kerri A.
f8af7188-2510-4c11-8a87-24b8d05c374c
Strâmbu, Irina
3dae037f-9dc6-4b35-9ef2-fb50ade0e6b6
Ravaglia, Claudia
785f7a4c-97f9-4912-a675-4be0992c220b
Grutters, Jan C.
684f7661-eab9-4d0f-97b6-45944fc899a0
Valenzuela, Claudia
80b6c1ba-7e18-4f0e-82a2-63c95da112e6
Mogulkoc, Nesrin
433ea942-9ac8-4c78-86a3-f1d003043852
Luppi, Fabrizio
7da8f1e6-4f08-4bcb-ae57-8bb3ce9032a5
Richeldi, Luca
47177d9c-731a-49a1-9cc6-4ac8f6bbbf26
Wells, Athol U.
47bba0f1-7cf9-4e3d-97b3-2be719a87357
Vancheri, Carlo
5f7ca838-5321-4639-ac93-0d924fd4bb73
Kreuter, Michael
f97455b8-d063-4e97-b0d2-c8bc715d04a2
Jones, Mark
a6fd492e-058e-4e84-a486-34c6035429c1
Johannson, Kerri A., Strâmbu, Irina, Ravaglia, Claudia, Grutters, Jan C., Valenzuela, Claudia, Mogulkoc, Nesrin, Luppi, Fabrizio, Richeldi, Luca, Wells, Athol U., Vancheri, Carlo and Kreuter, Michael
,
Erice ILD Working Group
(2017)
Antacid therapy in idiopathic pulmonary fibrosis.
The Lancet Respiratory Medicine, 5 (7), .
(doi:10.1016/S2213-2600(17)30219-9).
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of complex cause. Gastro-oesophageal reflux (GER) and microaspiration have been proposed as risk factors for the development and progression of IPF, but robust definitive data are few. A recent international guideline conditionally recommended the use of antacid therapy (proton pump inhibitors or histamine-2-receptor antagonists) for patients with IPF, in the absence of oesophageal reflux or symptoms. In this Position Paper, we summarise the literature addressing the association between GER and IPF, and also identify future research priorities that could clarify this issue. We shed light on the process through which the guideline recommendation was achieved and aim to contextualise the recommendation for providers caring for patients with IPF.
This record has no associated files available for download.
More information
e-pub ahead of print date: 23 June 2017
Published date: July 2017
Keywords:
Antacids/therapeutic use, Disease Progression, Gastroesophageal Reflux/complications, Histamine H2 Antagonists/therapeutic use, Humans, Idiopathic Pulmonary Fibrosis/complications, Practice Guidelines as Topic, Proton Pump Inhibitors/therapeutic use, Risk Factors, Severity of Illness Index
Identifiers
Local EPrints ID: 442205
URI: http://eprints.soton.ac.uk/id/eprint/442205
ISSN: 2213-2600
PURE UUID: b36929fb-8f6b-460f-a6d5-0e017826c0eb
Catalogue record
Date deposited: 08 Jul 2020 16:39
Last modified: 17 Mar 2024 03:11
Export record
Altmetrics
Contributors
Author:
Kerri A. Johannson
Author:
Irina Strâmbu
Author:
Claudia Ravaglia
Author:
Jan C. Grutters
Author:
Claudia Valenzuela
Author:
Nesrin Mogulkoc
Author:
Fabrizio Luppi
Author:
Luca Richeldi
Author:
Athol U. Wells
Author:
Carlo Vancheri
Author:
Michael Kreuter
Corporate Author: Erice ILD Working Group
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
